Oral cancer
Conditions
Interventions
Sponsors
Peking University School and Hospital of Stomatology
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Oral cancer diagnosed by pathological biopsy; The Presence of initial resectable diseases judged by the investigator Indications for neoadjuvant therapy:Locally advanced oral cancer: clinical stage III or above, cT3-4 or N+, no distant metastasis;Other patients considered suitable for inclusion and neoadjuvant therapy after MDT discussion. No previous tumor-related treatment including chemotherapy, radiotherapy, and immunotherapy; No other malignancy previously diagnosed, or a malignancy diagnosed with a favorable prognosis, such as basal cell carcinoma of the skin. Patients who can tolerate neoadjuvant therapy ECOG fitness status is less than or equal to 2 Expected survival time is no less than 6 months At least 1 measurable lesion (according to RECIST1.1) Voluntarily join this study, sign the informed consent form, have good compliance and be willing to cooperate with follow-up visits
Exclusion criteria
Exclusion criteria: Participate in other clinical trials within 6 months; Major surgery not related to oral cancer within 4 weeks, or the patient has not fully recovered from such a surgical procedure; Pregnant and lactating women; Serious comorbidities that interfere with treatment plans; Severe liver and kidney dysfunction and inability to tolerate chemotherapy; Cognitive impairment, mental illness, poor compliance; Hypersensitivity to known drug ingredients; Other circumstances in which the researchers consider not suitable to participate in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| clinical objective response rate;PTC susceptibility result; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pathological Response Rate; | — |
Countries
China
Contacts
Public ContactShan Xiaofeng
Peking University School and Hospital of Stomatology
Outcome results
None listed